<b>Background</b>: Neoadjuvant chemotherapy plus dual HER2 blockade is standard for HER2-positive early breast cancer (EBC), but the impact of hormone receptor (HR) status and <i>PIK3CA</i> mutations with anthracycline-free regimens remains unclear. The gene discussed is PIK3CA; the disease is breast carcinoma.